329 related articles for article (PubMed ID: 23358719)
1. Detection of circulating tumor cells in different stages of prostate cancer.
Thalgott M; Rack B; Maurer T; Souvatzoglou M; Eiber M; Kreß V; Heck MM; Andergassen U; Nawroth R; Gschwend JE; Retz M
J Cancer Res Clin Oncol; 2013 May; 139(5):755-63. PubMed ID: 23358719
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
3. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
Gu T; Li J; Chen T; Zhu Q; Ding J
Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467
[TBL] [Abstract][Full Text] [Related]
7. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
[TBL] [Abstract][Full Text] [Related]
8. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
[TBL] [Abstract][Full Text] [Related]
12. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
13. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
14. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
[TBL] [Abstract][Full Text] [Related]
15. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
[TBL] [Abstract][Full Text] [Related]
16. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.
Resel Folkersma L; San José Manso L; Galante Romo I; Moreno Sierra J; Olivier Gómez C
Urology; 2012 Dec; 80(6):1328-32. PubMed ID: 23063057
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
